News & Updates
Search Research Content
Resource Finder at Kennedy Krieger Institute
A free resource that provides access to information and support for individuals and families living with developmental disabilities.
Novel conjugation of tumor-necrosis-factor-related apoptosis-inducing ligand (TRAIL) with monomethyl auristatin E for efficient antitumor drug delivery.
|Title||Novel conjugation of tumor-necrosis-factor-related apoptosis-inducing ligand (TRAIL) with monomethyl auristatin E for efficient antitumor drug delivery.|
|Publication Type||Journal Article|
|Year of Publication||2013|
|Authors||Pan L-Q, Wang H-B, Xie Z-M, Li Z-H, Tang X-J, Xu Y-C, Zhang C, Naranmandura H, Chen S-Q|
|Journal||Advanced materials (Deerfield Beach, Fla.)|
|Date Published||2013 Sep 14|
Monomethyl auristatin E (MMAE) is conjugated with TNF-related apoptosis-inducing ligand (TRAIL) via a linker that is stable in extracellular fluid, while it is cleaved by cathepsin once the conjugate has entered a tumor cell, thus activating the antimitotic mechanism of MMAE. The TRAIL-MMAE conjugate is a conceptually viable therapeutic strategy with improved in vitro antitumor activity, cell circle arrest and specific accumulation in tumor to treat TRAIL-resistant tumors.
|Alternate Journal||Adv. Mater. Weinheim|